ShareholdingJun 18, 2026, 08:32 AM
BioForce Nanosciences Undergoes Control Change, Business Pivot
AI Summary
BIOFORCE NANOSCIENCES HOLDINGS, INC. announced a change in control as Merle Ferguson sold his 79.65% controlling stake, comprising 26,700,000 shares, to Nexus Capital Investments, Inc. for $400,000. This transaction was followed by significant management changes, including the resignations of Co-CEOs Steven Gagnon and John LaViolette, and Vice-President Sasha Shapiro. The Board appointed Scott Mager as a new Director and named Richard Kaiser as interim CEO, who also continues as CFO and Secretary. Additionally, the company is undergoing a major strategic pivot, shifting its business focus from the vitamin supplement industry to the oil and gas industry.
Key Highlights
- Merle Ferguson sold 26,700,000 shares, representing 79.65% of common stock.
- Nexus Capital Investments, Inc. acquired the controlling stake for $400,000.
- Co-Chief Executive Officers Steven Gagnon and John LaViolette, and VP Sasha Shapiro resigned.
- Scott Mager was appointed as a new Director effective June 15, 2026.
- Richard Kaiser was appointed interim CEO, retaining his CFO and Secretary roles.
- Company is changing business operations from vitamin supplements to the oil and gas industry.
- The Board of Directors now consists of Merle Ferguson, Richard Kaiser, and Scott Mager.
Price Impact
More from BFNH